Jennifer J. Knox
Surgery · 2009–2020
A researcher in the Science corpus: 9 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Surgery — 25 citations into it
- Statistics and Probability — 10 citations into it
Whom Jennifer J. Knox trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Jennifer J. Knox's perspective
Ordered by how strongly the researchers Jennifer J. Knox trusts endorse each paper. Same corpus, a different order for every researcher.
- Hallmarks of cancer: the next generation. (Cell)
- SEER Cancer Statistics Review, 1975-2003
- Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. (The Lancet Oncology)
- Cochrane Handbook for Systematic Reviews of Interventions (International Coaching Psychology Review)
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (New England Journal of Medicine)
- Genomic analyses identify molecular subtypes of pancreatic cancer (Nature)
- Immunity, Inflammation, and Cancer (Cell)
- Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. (Future Oncology)
- The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. (Cancer Treatment Reviews)
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. (Journal of Clinical Oncology)
Their papers
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) — 1,988 citations
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) — 898 citations
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (2019) — 1,410 citations
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2018) — 839 citations
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (2018) — 2,061 citations
- Integrated genomic characterization of oesophageal carcinoma (2017) — 1,666 citations
- Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. (2014) — 3,049 citations
- Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. (2013) — 774 citations
- Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. (2012) — 671 citations